Revance Therapeutics Inc. (RVNC)

Business: Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

IPO Date: 06-Feb-2014

CEO & Director: Mr. Mark J. Foley

Pres: Mr. Dustin S. Sjuts

Listing: NASDAQ: RVNC

Country: United States

Headquarters: Nashville, TN

Website: https://www.revance.com

Market cap: $1,042.77 Mln

Revenue (TTM): $89.76 Mln

Earnings (TTM): $-274.01 Mln

Cash: $262.59 Mln

Total Debt: $492.47 Mln

Insider's Holding: 2.66%

Liquidity: Low

52 Week range: $11.27 - 33.83

Shares outstanding: 72,768,200

10 Years Aggregate:

• CFO: $-963.03 Mln
• EBITDA: $-1,203.26 Mln
• Net Profit: $-1,322.35 Mln